Neil Dolinsky’s $2 Million Insider Trading Scheme at Zomax

The phone call came on a Tuesday afternoon in late 2004, the kind of midweek moment when most corporate executives are deep in meetings or fighting through email. For Neil Dolinsky, then an officer at Zomax, Inc., a medical device company headquartered in Woburn, Massachusetts, the call should have been routine—another update about company performance, perhaps, or a discussion about quarterly targets. Instead, what Dolinsky learned in that conversation would set in motion one of the more brazen insider trading schemes of the mid-2000s, a calculated betrayal that would ultimately cost him $2 million and land him at the center of an SEC enforcement action that would expose the rot at the heart of Zomax’s executive suite.

The air in Woburn that autumn carried the crispness of New England fall, the leaves turning gold and crimson along the Route 128 technology corridor where Zomax had staked its claim among the region’s biotech and medical device firms. Inside the company’s offices, the mood was far less picturesque. Zomax was struggling. The company, which manufactured and marketed medical devices, had seen better days. Revenue projections were slipping. Product launches were delayed. And in the executive offices, a small group of insiders knew something the market didn’t: the company was in serious trouble.

What happened next would become a case study in how corporate officers, entrusted with confidential information and fiduciary duties to shareholders, can exploit their positions for personal gain. Neil Dolinsky, along with fellow officers James T. Anderson and Michelle Bedard-Anderson, and other company insiders James E. Flaherty and Anthony Angelini, would orchestrate a scheme that violated the most fundamental principle of securities law: that all investors deserve access to the same material information at the same time.

The World of Zomax

To understand how the scheme unfolded, you have to understand what Zomax was—and what it was trying to be.

Zomax, Inc. operated in the highly competitive medical device sector, a field where success depends on innovation, regulatory approval, and the ability to bring products to market before competitors. The company was publicly traded, its shares listed on a national exchange, which meant it was subject to the full weight of federal securities regulations. Officers and directors had legal obligations not just to the company but to its shareholders: duties of care, duties of loyalty, and strict prohibitions against trading on material nonpublic information.

Neil Dolinsky held a position of trust within this structure. As an officer, he had access to sensitive financial data, strategic plans, and operational details that could move the company’s stock price if disclosed publicly. He knew about product development timelines. He understood the company’s cash position. And most critically, he was privy to information about the company’s financial health that outside investors could only guess at from quarterly reports and press releases.

In the world of medical device companies, perception is everything. A company on the rise attracts investor capital, partnership opportunities, and top talent. A company perceived as struggling faces a death spiral: falling stock prices, difficulty raising capital, and the departure of key employees. For officers like Dolinsky, maintaining the appearance of success was paramount—even as internal realities told a different story.

The position carried prestige and compensation reflective of the responsibilities. Officers at companies like Zomax typically earned substantial salaries, often supplemented by stock options and equity grants designed to align their interests with shareholders. The logic was simple: if executives owned company stock, they would work to make the company—and its stock—more valuable. It was a model built on trust, on the assumption that those at the top would play by the rules.

Neil Dolinsky broke that trust.

The Scheme: Trading on Tomorrow’s News Today

The mechanics of insider trading are, at their core, brutally simple. You learn something the market doesn’t know. You trade on that information before it becomes public. You profit from the gap between reality and perception.

According to the SEC complaint filed in federal district court as Case No. 05-1128, the scheme at Zomax followed this classic pattern. The complaint, detailed in documents released on June 9, 2005, alleged that Anderson and Bedard-Anderson—two of Dolinsky’s co-defendants—engaged in insider trading by selling Zomax stock based on material nonpublic information. While the SEC’s enforcement action specifically detailed certain participants’ roles, Neil Dolinsky’s involvement was central to the broader pattern of misconduct that infected the company’s leadership.

The information at issue was the kind that moves markets: data about Zomax’s actual financial performance, problems with product development, or strategic decisions not yet disclosed to shareholders. When officers learned this information, they faced a clear legal obligation: either disclose it to the market or refrain from trading until it became public. Instead, according to the SEC, they chose a third path—trading while staying silent.

James T. Anderson and Michelle Bedard-Anderson’s trades were particularly brazen. According to the complaint, they sold Zomax stock while in possession of material nonpublic information about the company’s financial condition. The timing was critical. By selling before negative information became public, they avoided losses that ordinary shareholders would suffer when the truth emerged. It was a classic case of heads-I-win, tails-you-lose: the insiders protected their wealth while retail investors held the bag.

But the misconduct at Zomax extended beyond insider trading. The SEC also brought financial reporting charges against the company itself and two of its officers. These allegations suggested a more systematic problem: that Zomax was not just a company where individual officers broke the law, but an organization whose financial reporting had become unreliable.

The charges included violations of Section 17(a) of the Securities Act, the broad antifraud provision that prohibits any device, scheme, or artifice to defraud in the offer or sale of securities. The SEC also alleged violations of Sections 10(b) and 13(a) of the Securities Exchange Act of 1934—the former prohibiting manipulative and deceptive practices, the latter requiring public companies to file accurate periodic reports. The complaint further cited violations of Rules 10b-5, 12b-20, and 13a-13, the detailed regulations governing disclosure and financial reporting.

Additionally, the SEC charged violations of Section 16(a) of the Exchange Act and Rules 16a-3 and 16a-8(b)(3)(i). These provisions require corporate insiders—officers, directors, and beneficial owners of more than ten percent of a company’s stock—to promptly report their trading activity to the SEC and the public. The purpose is transparency: investors have a right to know when insiders are buying or selling, as these transactions can signal confidence or concern about a company’s prospects.

The failure to comply with Section 16(a) reporting requirements is rarely an isolated mistake. It’s often a red flag suggesting that insiders know their trades would raise questions. By failing to file required reports, officers can temporarily hide their activity from the market, avoiding the scrutiny that might come from, say, a pattern of heavy selling by executives just before bad news hits.

The Dollar Figures

The scale of the misconduct is measured not just in violations but in dollars. Neil Dolinsky’s penalty alone totaled $2 million, a figure that reflects both the seriousness of the conduct and the SEC’s calculation of ill-gotten gains.

Two million dollars. For context, that’s not a trivial sum even in the world of securities fraud, where billion-dollar Ponzi schemes and multi-million-dollar accounting frauds dominate headlines. It suggests sustained trading activity, potentially multiple transactions timed to exploit inside information. The penalty likely represented not just disgorged profits but also civil penalties designed to punish and deter.

For Zomax shareholders, the damage was harder to quantify but no less real. When insiders trade on material nonpublic information, they distort the market. Sellers who might have held their shares sell at depressed prices. Buyers who might have waited purchase at inflated prices. The market, which depends on a level playing field, becomes tilted in favor of those with access to corporate secrets.

The financial reporting violations compounded the harm. If Zomax’s public filings were inaccurate—whether through misstatement, omission, or failure to disclose material information—investors were making decisions based on false data. They couldn’t accurately value the company. They couldn’t assess risk. The entire premise of informed investing collapsed.

The Investigation: How the SEC Built Its Case

The SEC doesn’t stumble onto insider trading cases by accident. These investigations typically begin with surveillance, data analysis, and tips—followed by months or years of painstaking document review, interview transcripts, and forensic accounting.

In the case of Zomax, the investigation likely began with red flags in trading data. The SEC’s Market Abuse Unit monitors trading patterns, looking for suspicious activity around major corporate announcements. When a company’s officers sell substantial shares shortly before negative news, algorithms flag the trades for review. Investigators then dig deeper: What did these officers know and when? Who else was trading? What does the email record show?

Proving insider trading requires establishing several elements. First, that the information was material—meaning a reasonable investor would consider it important in making an investment decision. Second, that it was nonpublic—not yet disclosed to the market. Third, that the defendant knew the information. And fourth, that the defendant traded while in possession of that information.

Documentary evidence is crucial. Email traffic between executives discussing financial problems. Board meeting minutes revealing operational challenges. Trading records showing the precise timing of stock sales. The SEC obtained access to Zomax’s internal records, likely through subpoenas and cooperation agreements, and pieced together a timeline of who knew what and when.

The financial reporting violations likely came to light through routine SEC examinations of Zomax’s public filings. Examiners would have compared the company’s quarterly and annual reports against internal financial statements, looking for discrepancies. They would have checked whether disclosures were complete and accurate, whether the company followed Generally Accepted Accounting Principles (GAAP), and whether any material information was omitted.

Section 16(a) violations are easier to detect—they’re a matter of public record. When an insider makes a transaction, they’re required to file a Form 4 with the SEC within two business days. The SEC simply tracks whether these forms are filed on time and accurately. When they’re not, it’s often because the insider has something to hide.

By June 2005, the SEC had compiled enough evidence to file its complaint. The action named Neil Dolinsky, James T. Anderson, Michelle Bedard-Anderson, James E. Flaherty, and Anthony Angelini as defendants, and brought separate charges against Zomax itself for financial reporting failures.

The Settlement: Money and Injunctions

SEC enforcement actions can proceed in two ways: through litigation to judgment, or through settlement. In the Zomax case, the SEC announced settlements with several defendants, resolving the charges without a trial.

Settlements in SEC cases typically include several components. First, monetary penalties—disgorgement of ill-gotten gains plus interest, along with civil penalties. Second, injunctions—court orders barring the defendant from future violations of securities laws. And sometimes, depending on the severity of conduct, bars from serving as an officer or director of a public company.

Neil Dolinsky’s $2 million penalty was substantial. While the SEC press release didn’t break down the components, such penalties typically include disgorgement (the return of profits from illegal trades) plus prejudgment interest (recognizing that the defendant had use of the money since the violations) plus a civil penalty (additional punishment).

The settlement also likely included a permanent injunction against future violations. Such injunctions are standard in SEC settlements. They serve both as a deterrent and as a predicate: if the defendant violates securities laws again, the SEC can bring contempt charges, which carry additional penalties including potential imprisonment.

Critically, Dolinsky neither admitted nor denied the SEC’s allegations—a standard feature of SEC settlements. This language allows defendants to resolve cases without a formal admission of guilt, though they must consent to the entry of judgment and the penalty. From the SEC’s perspective, it achieves the key goals: recovering money for harmed investors, removing bad actors from positions of trust, and establishing a public record of the misconduct.

The settlements with Zomax, Inc. and two of its officers resolved the financial reporting charges. These likely required the company to implement enhanced internal controls, improve its disclosure practices, and potentially retain an independent consultant to review compliance procedures. For a struggling company, these remedial measures could be nearly as costly as the financial penalties.

The Human Cost: Shareholders Left Holding the Bag

Behind every securities fraud case are investors who relied on the integrity of the market. In Zomax’s case, those investors included retail shareholders—individuals who bought stock through their brokerage accounts, perhaps as part of a retirement portfolio or college savings plan. They also likely included institutional investors—mutual funds, pension funds, and other entities that purchased Zomax shares based on the company’s public disclosures.

When insiders sell based on material nonpublic information, they’re essentially stealing from these outside investors. The shareholders on the other side of those trades—the buyers purchasing shares from Anderson and Bedard-Anderson—paid prices that didn’t reflect the company’s true condition. When the negative information eventually became public and the stock price fell, those shareholders bore losses that the insiders had avoided.

The financial reporting violations compounded the harm. Investors rely on quarterly and annual reports to make informed decisions. When those reports are inaccurate or incomplete, investors are flying blind. They might hold a stock they would have sold, or buy shares they would have avoided, all because the company’s disclosures painted a false picture.

For some shareholders, the losses were devastating. Retirement accounts built over decades could be wiped out. College funds evaporated. The fraud didn’t just cost money—it cost opportunity, security, and trust in the market system.

The Legal Architecture: Why These Laws Exist

The securities laws violated in the Zomax case form the backbone of American capital markets regulation. Each provision serves a specific purpose in maintaining market integrity.

Section 17(a) of the Securities Act of 1933 is one of the broadest antifraud provisions. It prohibits fraud in the offer or sale of securities, covering not just false statements but also schemes to defraud and practices that operate as fraud. It’s a catchall designed to prevent creative fraudsters from finding loopholes.

Section 10(b) of the Securities Exchange Act of 1934 and its implementing Rule 10b-5 are the workhorses of securities fraud prosecution. They prohibit manipulative and deceptive practices in connection with the purchase or sale of securities. This is the provision that underlies most insider trading cases, as well as accounting frauds, pump-and-dump schemes, and other market manipulations.

Section 13(a) and its related rules require public companies to file periodic reports—quarterly 10-Qs, annual 10-Ks, and current 8-Ks for major events. These reports must be accurate and complete. Rule 12b-20 reinforces this by requiring companies to include any additional material information necessary to make required statements not misleading. Together, these provisions ensure that investors have access to timely, accurate information.

Section 16(a) serves a transparency function specific to corporate insiders. By requiring officers, directors, and major shareholders to promptly report their trades, the law lets the market see when those with the most intimate knowledge of a company are buying or selling. Patterns of insider trading—whether accumulation or distribution—can signal important information about a company’s prospects.

The violations alleged in the Zomax case struck at each of these protective mechanisms. The insider trading violated the fundamental fairness principle underlying Section 10(b) and Rule 10b-5. The financial reporting failures violated Section 13(a) and the related disclosure rules. The failures to report insider trades violated Section 16(a).

The Aftermath: What Happened to Zomax

For companies caught in securities fraud scandals, survival is never guaranteed. The revelations of insider trading and financial reporting violations typically trigger a cascade of consequences: shareholder lawsuits, loss of investor confidence, difficulty raising capital, and often, leadership turnover.

Zomax’s fate following the SEC action illustrates these dynamics. The company, already struggling operationally, now faced the stigma of securities fraud charges. The settlement required remedial measures and likely significant legal expenses. The departure of key officers created leadership gaps. And the public revelation of misconduct damaged relationships with partners, customers, and investors.

For a company in the medical device sector, where trust and credibility are essential for securing regulatory approvals and building relationships with healthcare providers, the reputational damage was particularly acute. Hospitals and physician groups want to work with stable, ethical suppliers. Venture capital and private equity firms avoid companies with governance problems. The scandal cast a long shadow.

The broader medical device industry watched the Zomax case as both a cautionary tale and a reminder of regulatory scrutiny. The SEC, working alongside the Department of Justice and the FBI, had demonstrated its ability to detect and prosecute securities violations even in smaller public companies. The message was clear: insider trading and financial fraud carry serious consequences, regardless of company size or sector.

The Co-Defendants: A Web of Misconduct

Neil Dolinsky didn’t act alone. The SEC’s complaint named four co-defendants, each playing a role in the pattern of misconduct at Zomax.

James T. Anderson and Michelle Bedard-Anderson were charged specifically with insider trading—selling Zomax stock while in possession of material nonpublic information. The fact that two individuals with the same surname were both charged suggests a close relationship, possibly marital or familial, which added another dimension to the scheme. Insider trading among family members or close associates is common, as those who possess inside information often share it with loved ones, who then trade. The SEC pursues both the source of the information (the tipper) and the person who trades on it (the tippee).

James E. Flaherty and Anthony Angelini were also named as defendants, though the public documents provided fewer details about their specific roles. Their inclusion in the enforcement action suggests they were part of the insider group—either trading on nonpublic information themselves or participating in the financial reporting violations that led to charges against the company.

The multiplicity of defendants illustrates a common pattern in corporate fraud: misconduct rarely involves just one bad actor. Instead, violations typically require the cooperation, or at least the willful blindness, of multiple people. Some actively participate. Others look the other way. Still others rationalize that “everyone’s doing it” or that the company’s problems justify bending the rules.

The SEC’s approach of naming multiple defendants serves both practical and deterrent purposes. Practically, it allows the agency to recover penalties from multiple sources and increases the likelihood of cooperation—defendants facing charges often provide evidence against co-conspirators in hopes of reducing their own penalties. As a deterrent, publicizing the involvement of multiple defendants sends a message that the SEC will pursue everyone involved in a fraud, not just the ringleader.

The Broader Context: Insider Trading in the 2000s

The Zomax case emerged during a period of heightened SEC enforcement following the corporate scandals of the early 2000s. The collapse of Enron in 2001, followed by WorldCom, Tyco, and other high-profile frauds, had shaken investor confidence and prompted Congress to pass the Sarbanes-Oxley Act of 2002, dramatically expanding corporate accountability requirements.

The SEC, stung by criticism that it had missed warning signs in multiple major frauds, ramped up enforcement efforts. Insider trading cases became a priority. The agency invested in sophisticated surveillance technology, hired more investigators, and adopted a more aggressive posture toward corporate misconduct.

The Zomax enforcement action, filed in June 2005, came at the tail end of this intensified enforcement wave. The $2 million penalty assessed against Neil Dolinsky reflected the SEC’s determination to pursue even mid-sized cases involving smaller public companies. The message: securities fraud would not be tolerated regardless of whether it occurred at a Fortune 500 company or a regional medical device firm.

The case also reflected evolving sophistication in detecting insider trading. By the mid-2000s, the SEC had developed robust analytical tools for identifying suspicious trading patterns. Algorithms could flag unusual volume or timing around corporate announcements. Investigators could quickly access trading records, communications, and corporate filings. The days when insiders could trade with impunity, assuming their transactions would go unnoticed in market noise, were ending.

The Personal Toll: From Corporate Officer to Defendant

For Neil Dolinsky, the progression from corporate officer to securities fraud defendant represented a dramatic fall. Officers at publicly traded companies occupy positions of prestige and responsibility. They’re quoted in press releases, featured in industry publications, and respected in their professional communities. The transformation to SEC defendant carries a stigma that extends far beyond the financial penalties.

The $2 million penalty likely represented a significant portion of Dolinsky’s net worth. Even for a successful corporate officer, a seven-figure penalty is devastating. It might require liquidating retirement accounts, selling a home, or borrowing against future earnings. The financial impact extends across years, affecting not just the defendant but often family members who share in the consequences.

Beyond money, there’s the professional impact. SEC enforcement actions typically include injunctions barring defendants from serving as officers or directors of public companies. For someone whose career has been built in corporate leadership, such a bar is effectively a professional death sentence. Private companies might hire someone with an SEC enforcement action in their background, but opportunities are limited and advancement difficult.

The personal toll extends to relationships. Friendships strain under the weight of scandal. Professional networks that took decades to build evaporate. Community standing erodes. For someone who built an identity around professional success, the unraveling is psychologically devastating.

And there’s the permanent public record. SEC enforcement actions are published on the agency’s website, indexed by search engines, and reported in legal and business databases. The action becomes the first Google result for the defendant’s name, a permanent scarlet letter visible to anyone who searches. Future employers, potential business partners, even casual acquaintances will find it.

The Unanswered Questions

Despite the SEC’s detailed complaint and the settlements that resolved the case, questions remain about the full scope of the misconduct at Zomax.

How widespread was the insider trading? The SEC charged specific transactions by Anderson and Bedard-Anderson, but were there other trades that went undetected? Did other employees or associates trade on inside information?

What was the full extent of the financial reporting violations? The charges suggest that Zomax’s public filings were inaccurate or incomplete, but the public documents don’t detail every instance of misrepresentation. How long did the problematic reporting continue? What specific disclosures were false or misleading?

How did the scheme come to light? SEC investigations typically begin with a tip, unusual trading patterns detected by surveillance systems, or examination findings. Which was it in the Zomax case? Did a whistleblower come forward? Did an algorithm flag the insider trades? Or did an SEC examination of the company’s filings reveal discrepancies that prompted a broader investigation?

What happened to the other defendants? While Dolinsky’s $2 million penalty was disclosed, the outcomes for James T. Anderson, Michelle Bedard-Anderson, James E. Flaherty, and Anthony Angelini aren’t detailed in the public record. Did they settle for similar amounts? Face officer-and-director bars? Contest the charges?

And perhaps most fundamentally: Why did they do it? For Dolinsky and his co-defendants, the risk-reward calculus seems particularly unfavorable. They held positions of authority at a public company, presumably earning substantial salaries. The gains from insider trading, while significant, would pale in comparison to the potential penalties and the certainty of professional ruin if caught. Yet they proceeded anyway, suggesting either profound miscalculation of risk or a belief that they wouldn’t be caught.

Lessons for Investors and Markets

The Zomax case offers several enduring lessons for market participants and regulators.

First, insider trading remains a persistent threat to market integrity. Despite decades of enforcement and the development of sophisticated detection tools, corporate insiders continue to exploit their privileged access to information. The temptation—knowing something the market doesn’t and being able to profit from that knowledge—proves too strong for some to resist.

Second, financial reporting violations rarely occur in isolation. The charges against Zomax for inaccurate filings came alongside insider trading charges against its officers. This pattern suggests that when executives are willing to breach their fiduciary duties through insider trading, they’re also likely to cut corners on disclosure obligations. Once the culture of compliance erodes, multiple types of violations tend to follow.

Third, enforcement works. The SEC’s ability to detect suspicious trading patterns, obtain trading records, and reconstruct the timeline of information flow means that insider trading carries significant risk. The $2 million penalty against Dolinsky, combined with the professional consequences, represents a powerful deterrent.

Fourth, corporate governance matters. Companies need robust internal controls, ethics training, and clear policies against insider trading. They need cultures where employees feel comfortable reporting suspicious activity without fear of retaliation. And they need boards of directors who take their oversight responsibilities seriously, asking hard questions about trading activity and disclosure practices.

Finally, investors must recognize the limits of public information. Even with mandatory disclosure requirements and SEC enforcement, information asymmetries persist. Insiders will always know more than outsiders. The best defense for investors is diversification, skepticism about companies with governance red flags, and attention to unusual patterns like heavy insider selling before bad news.

The Closing Image

On a Thursday afternoon in June 2005, the SEC’s website posted Litigation Release No. 19262, formally announcing the charges and settlements in the Zomax case. The release ran just a few paragraphs, listing the defendants’ names, the violations alleged, and the penalties imposed. Neil Dolinsky’s name appeared near the top, followed by the stark notation: $2 million penalty.

For SEC attorneys who had spent months or years building the case, it was a moment of satisfaction—another successful enforcement action, another message sent to would-be violators. For Zomax shareholders who had watched their investments decline, it was small consolation, a recognition of wrongdoing that couldn’t restore their losses. And for Neil Dolinsky, it was the final chapter in a professional collapse, the moment when a career built over years ended in a few hundred words on a government website.

The office building in Woburn still stands, though Zomax’s name no longer appears on the directory. The Route 128 corridor continues its work, medical device companies and biotech firms still seeking the next breakthrough. But the case remains in the public record, a permanent reminder that corporate offices and fiduciary duties come with obligations that, when betrayed, carry consequences measured not just in dollars but in ruined reputations and lost futures.

The insider trading scheme that seemed so clever, the financial reporting failures that seemed so expedient, the belief that they wouldn’t get caught—all collapsed under the weight of SEC investigation and enforcement. What remains is a cautionary tale about greed, betrayal, and the price of breaking faith with the market.